Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has announced that its New Drug Application (NDA) for the self-developed drug, Tyrosine-9591 (甲磺酸艾多替尼片), targeting brain metastases of non-small cell lung cancer (NSCLC), has been officially accepted by the National Medical Products Administration (NMPA) in China, marking it as the first next-generation EGFR-TKI inhibitor for lung cancer brain metastases [1][5]. Group 1: Drug Development and Clinical Trials - The NDA submission is based on a pivotal registration clinical study (ESAONA) conducted in China, which is a multi-center, randomized, open-label, positive-controlled trial aimed at evaluating the efficacy and safety of Tyrosine-9591 compared to Osimertinib in NSCLC patients with brain metastases [3]. - The mid-term analysis of the ESAONA study, presented at the WCLC2025 conference, showed an intracranial objective response rate (iORR) of 92.8% for the Tyrosine-9591 group compared to 76.1% for the Osimertinib group, indicating a statistically significant difference [4]. - Tyrosine-9591 is designed for first-line treatment of adult patients with locally advanced or metastatic NSCLC who have EGFR exon 19 deletions or L858R mutations and central nervous system (CNS) metastases [2]. Group 2: Company Strategy and Future Outlook - The acceptance of the NDA into the priority review process by the NMPA is expected to expedite the drug's market launch, with ongoing studies on both monotherapy and combination therapy for Tyrosine-9591 [5]. - The company emphasizes its commitment to addressing unmet clinical needs and continues to explore clinical research for combination therapies to better serve patients with lung cancer brain metastases [6]. - The submission of the NDA represents a significant milestone for the company, marking its entry into the commercialization phase and reflecting its dedication to innovative drug development in the oncology field [6][8].
同源康医药肺癌脑转移新药艾多替尼上市申请获正式受理并纳入优先审评